Jim Wassil - 01 Mar 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role: Chief Operating Officer
Signature: Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol: PCVX
Transactions as of: 01 Mar 2023
Net transactions value: -$49,332
Form type: 4
Filing time: 03 Mar 2023, 16:10:36 UTC
Previous filing: 04 Jan 2023
Next filing: 08 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCVX	Common Stock	Award	$0	+22,500	+15%	$0.000000	170,215	01 Mar 2023	Direct	F1
transaction	PCVX	Common Stock	Tax liability	$49,332	-1,189	-0.7%	$41.49	169,026	02 Mar 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCVX	Stock Option (right to buy)	Award	$0	-135,000	-50%	$0.000000	135,000	01 Mar 2023	Common Stock	135,000	$41.67	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2	Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F3	1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.